Theravance Biopharma Inc Dossier
Qualitative Analysis
Business overview
Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the development and commercialization of organ-selective medicines. The company's commercial portfolio is anchored by YUPELRI (revefenacin) inhalation solution, a once-daily nebulized long-acting muscarinic antagonist (LAMA) approved in the United States for the maintenance treatment of chronic obstructive pulmonary disease (COPD), developed and commercialized in collaboration with Viatris Inc.. Following the clinical failure of its late-stage candidate ampreloxetine in the Phase 3 CYPRESS study for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA) in March 2026, Theravance Biopharma initiated a major strategic pivot. This pivot includes winding down its research and development (R&D) function and significantly reducing its general and administrative (G&A) expenses to transition into a commercial-stage entity focused on maximizing the cash-flow generation of YUPELRI and its royalty streams.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Winding down the internal research and development (R&D) function and significantly reducing the general and administrative (G&A) function following the Phase 3 CYPRESS study of ampreloxetine failing to meet its primary endpoint.
Expected impact: A reduction in operating expenses of approximately 60% relative to 2025 actuals, yielding approximately $70 million in annualized cost savings and enabling the company to generate $60 million to $70 million of annualized cash flow starting in Q3 2026.
Aligning corporate resources to maximize the commercial value and adoption of YUPELRI (revefenacin) inhalation solution in the U.S. hospital and community channels.
Expected impact: Sustained net sales growth, expanding brand-level profitability, and increased long-term franchise value, supported by growing adoption and resolved generic patent litigation.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Viatris leads the commercialization of YUPELRI (revefenacin) in the U.S., while Theravance Biopharma co-promotes the product under a 65% (Viatris) / 35% (Theravance) profit and loss sharing arrangement.
Terms: Theravance Biopharma receives its 35% share of net sales of YUPELRI and is eligible for potential development, regulatory, and sales milestone payments.
Theravance sold its TRELEGY royalty rights to Royalty Pharma but retained the rights to receive sales-based milestone payments.
Terms: Theravance received a $50 million milestone payment in February 2026 based on 2025 TRELEGY sales and is eligible to receive an additional $100 million milestone payment if 2026 global net sales of TRELEGY reach approximately $3.5 billion.
Resolves all pending Hatch-Waxman patent litigation relating to YUPELRI, securing long-term patent-based protections for the franchise.
Terms: Theravance and Viatris granted Mankind a royalty-free, non-exclusive license to manufacture and market a generic version of YUPELRI in the United States on or after April 23, 2039.